We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Developers Voice Concern Over Draft Orphan Drug Loophole Guidance
Developers Voice Concern Over Draft Orphan Drug Loophole Guidance
FDA guidance that proposes to close what the agency sees as a “loophole” allowing drug developers to bypass pediatric study requirements would negatively impact child drug development if it becomes final, according to some drug developers and patient advocacy groups.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor